Reata Pharmaceuticals

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Reata Pharmaceuticals advances SKYCLARYS, faces impurity challenges and growth opportunities

Reata Pharmaceuticals is making significant progress with FDA approvals and commercialization plans for SKYCLARYS. The company is strategically managing resources and focusing on key programs for long-term sustainability. Challenges with impurity issues and discontinuation of bardoxolone program are being addressed while opportunities for label expansion and new asset exploration are being pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases. It offers antioxidant and inflammation-modulating drugs, as well as drugs that correct protein misfolding. The company also develops drugs for the treatment of renal, cardiovascular, and autoimmune diseases. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005.

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that the United States Food and Drug Administration (FDA) has approved the Prior Approval Supplement (PAS) to update the drug substance specification for SKYCLARYS® (omaveloxolone), the first and only FDA approved drug for the treatment o.

Reata Pharmaceuticals Announces Approval of Prior Approval Supplement for SKYCLARYS® (Omaveloxolone) and Commercial Availability of SKYCLARYS for Patients with Friedreich's Ataxia

A Prior Approval Supplement for Reata Pharmaceuticals, Inc.'s SKYCLARYS for Friedreich's Ataxia has been submitted with a Priority Review Date of Mid-August 2023. It is expected that the global Friedreich's Ataxia market could reach $2.06 billion by 2030. A phase 2 study using Cemdomespib for the treatment of patients with diabetic peripheral neuropathy is expected to start in Q3 of 2023.

Reata: FDA Approval Of SKYCLARYS Isn't Only Driver Moving Forward

Reata (RETA) gets FDA acceptance for the filing of new drug application supplement approval for Skyclarys' release.

Reata (RETA) Announces FDA's Acceptance of Skyclarys PAS

Reata took a step closer to launching its highly anticipated Friedreich's ataxia drug on Friday with a new FDA filing, and RETA stock jumped.

Top 1% Biotech Stock Reata Pharmaceuticals Faces Another Hurdle

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced today that the U.S. Food and Drug Administration (FDA) accepted for filing the Prior Approval Supplement (PAS) to update the drug substance specification for SKYCLARYS® (omaveloxolone). As per the US Code of Federal Regulation, the filing.

Reata Pharmaceuticals Announces FDA Filing Acceptance of SKYCLARYS® (Omaveloxlone) NDA Prior Approval Supplement

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced the appointment of Rajiv Patni, M.D., as Executive Vice President, and Chief Research & Development Officer. Dr. Patni will report to Warren Huff, Chief Executive Officer, and will be responsible for overseeing the Company's research a.

Reata Pharmaceuticals Appoints Rajiv Patni, M.D., as Executive Vice President, Chief Research & Development Officer

NEW YORK , June 12, 2023 /PRNewswire/ -- Attention Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ: RETA) shareholders: The Law Offices of Vincent Wong announce that an investigation has commenced into Reata and certain of its officers and directors regarding potential securities fraud. The investigation concerns, in part, the below: On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023.

RETA ALERT: The Law Offices of Vincent Wong Investigate Reata Pharmaceuticals, Inc. for Potential Violations of Securities Laws

Reata Pharmaceuticals, Inc. (RETA) reported earnings 30 days ago. What's next for the stock?

Why Is Reata Pharmaceuticals, Inc. (RETA) Up 6.9% Since Last Earnings Report?

NEW YORK , June 9, 2023 /PRNewswire/ -- Jakubowitz Law announces that an investigation into potential securities fraud allegations has commenced on behalf of shareholders of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) To be contacted by a member of our team, fill out the form: https://claimyourloss.com/securities/reata-class-action-loss-submission-form/?id=40550&from=4 Further details on the investigation: On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023. Among other items, Reata announced its decision to discontinue studies for its kidney disease candidate bardoxolone, which the Company had previously advanced as one of its lead assets in partnership with Blackstone Life Sciences and Kyoma Kirin.

RETA FRAUD ALERT: Jakubowitz Law is Investigating Reata Pharmaceuticals, Inc. in Connection with Potential Violations of Federal Securities Laws

NEW YORK , June 8, 2023 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ: RETA) concerning possible violations of federal securities laws. On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023.

RETA INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, announced that management will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on June 12 – 15, 2023, in Dana Point, California. Manmeet Soni, Reata's President, Chief Operating Officer, and Chief Financial Officer will be.

Reata Pharmaceuticals Announces Participation in the Goldman Sachs 44th Annual Global Healthcare Conference

NEW YORK , May 31, 2023 /PRNewswire/ -- The Klein Law Firm announces that it is investigating allegations that Reata Pharmaceuticals, Inc. ("Reata") (NASDAQ: RETA) violated federal securities laws. CURRENT INVESTIGATION DETAILS: On May 10, 2023, Reata issued a press release announcing its financial results for the first quarter of 2023.

RETA NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Reata Pharmaceuticals, Inc.

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Reata Pharmaceuticals, Inc. (“Reata” or the “Company”) (NASDAQ: RETA) on behalf of Reata stockholders. Our investigation concerns whether Reata has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On May 10, 2023, Reata issued a press release announcing its fina.

REATA ALERT: Bragar Eagel & Squire, P.C. is Investigating Reata Pharmaceuticals, Inc. on Behalf of Reata Stockholders and Encourages Investors to Contact the Firm

Despite recent production hitches with Skyclarys and the halt of bardoxolone, Reata Pharmaceuticals remains a compelling investment prospect. The expedited FDA review of Skyclarys' NDA supplement underscores the drug's crucial role in treating Friedreich's ataxia.

Reata Pharmaceuticals: 'Buy' Following Skyclarys Delay And Bardoxolone Discontinuation (Rating Upgrade)

NEW YORK , May 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Reata Pharmaceuticals, Inc. ("Reata" or the "Company") (NASDAQ: RETA).  Such investors are advised to contact Robert S.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Reata Pharmaceuticals, Inc. - RETA

Reata (RETA) incurs wider-than-expected loss in the first quarter. The company discontinues the development of bardoxolone methyl for diabetic kidney disease.

Reata (RETA) Q1 Earnings Miss, Stock Dips on Pipeline Updates

Reata Pharmaceuticals, Inc. (NASDAQ:RETA ) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET Company Participants Warren Huff - Chairman and Chief Executive Officer Dawn Bir - Executive Vice President and Chief Commercial Officer Andrea Loewen - Senior Vice President of Global Regulatory Affairs Seemi Khan - Senior Vice President and Chief Medical Officer Colin Meyer - Executive Vice President and Chief Innovation Officer Manmeet Soni - President, Chief Operating Officer and Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Madhu Kumar - Goldman Sachs Yatin Suneja - Guggenheim Securities Charles Duncan - Cantor Fitzgerald Carter Gould - Barclays Annabel Samimy - Stifel Maury Raycroft - Jefferies Matthew Kaplan - Ladenburg Thalmann Operator Thank you for standing by, and welcome to the Reata Pharmaceuticals First Quarter Financial Results Update on Operational Progress and Development Programs Conference Call. An audio recording of today's webcast will be available shortly after the call in the Investor section of Reata's website at reatapharma.com.

Reata Pharmaceuticals, Inc. (RETA) Q1 2023 Earnings Call Transcript

Reata Pharmaceuticals is scrapping development of a kidney disease drug and put up mixed earnings Wednesday. RETA stock tumbled.

Reata Pharma Tumbles After Scrapping Its Kidney Drug As Earnings Come In Mixed

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases, today announced financial results for the first quarter of 2023 and provided an update on the Company's business operations and clinical development programs. “In the first quarter of 2023, we announced that the U.S. Food and Drug Administration (FD.

Reata Pharmaceuticals, Inc. Announces First Quarter 2023 Financial Results and Provides an Update on Operational Progress and Clinical Development Programs

PLANO, Texas--(BUSINESS WIRE)--Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a global, biopharmaceutical, company focused on developing and commercializing novel therapies for patients with severe diseases, today announced that it will report financial results for the first quarter ended March 31, 2023, and provide an update on the Company's business operations and clinical development programs on May 10, 2023, before the U.S. financial markets open.

Reata Pharmaceuticals, Inc. to Report First Quarter 2023 Financial Results and to Provide an Update on Operational Progress and Clinical Development Programs on May 10, 2023

Reata graduated to owning a commercial pharmaceutical product on February 28. Projecting timing for Skyclarys or any new therapy's revenue ramp is difficult.

Reata Pharmaceuticals: Still A Buy After Skyclarys Approval Jump

Aurinia Pharmaceuticals

Medtronic

Reata Pharmaceuticals earned approval for its first drug in February, and its stock price has been soaring ever since. The first new drug Aurinia Pharmaceuticals launched got off to a rocky start, but a strong end to 2022 caused the stock to soar this year, Orchestra BioMed is a medical technology developer that has an important partnership with Medtronic, the world's largest medical device manufacturer.

3 Stocks That Already Doubled in 2023 and Could Keep Climbing

Axsome Therapeutics

CRISPR Therapeutics

Investors may want to keep an eye on biotech growth stocks, which are typically associated with the risk-on trade. Case in point: The sector ran up in January, but when the broader-market rally fizzled, it sold off hard as investors sought safer havens.

The 3 Best Growth Stocks to Buy in the Biotech Sector

Calliditas Therapeutics AB

NeoGenomics

Reata Pharmaceuticals stock is soaring on the back of a recent FDA approval for a new rare disease drug. Calliditas Therapeutics stock recently jumped higher in response to positive trial results for its lead drug.

3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing

Reata Pharmaceuticals (RETA) stock more than doubles this year, owing to approval for its rare disease drug.

News for Reata Pharmaceuticals Stock (RETA)